Advertisement

Sekundärprävention der koronaren Herzkrankheit in der Praxis

  • M. Pichler

Zusammenfassung

Der Begriff „Sekundärprävention“ im Rahmen der koronaren Herzkrankheit (KHK) umschreibt Maßnahmen zur Senkung von Risikofaktoren bei Patienten, die bereits ein klinisches Ereignis wie Angina pectoris, einen Herzinfarkt, eine PTCA (perkutane transluminal Koronarangiographie) oder eine aortokoronare Bypassoperation (CABG) erlebt haben. Der epidemiologische Ausdruck „Prävention“ ist irreführend, vielmehr handelt es sich um ein generelles Management von Patienten mit bereits dokumentierter KHK. Maßnahmen zur Sekundärprävention werden auch bei der Rehabilitation subsumiert, welche der umfassendere Begriff ist und welche aufgrund des zeitlichen Zusammenhanges mit dem Ereignis, (s. Kap. 11.1) in verschiedene Stufen eingeteilt wird [76, 78, 89].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators (1995) The effect of the angiotensin-converting- enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332: 80–85Google Scholar
  2. 2.
    American Heart Association (1994) Cardiac rehabilitation programs: a statement for health care professionals from the American Heart Association (position statement). Circulation 90: 1602–1610Google Scholar
  3. 3.
    Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group (1994) Effect of long term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 343: 499–503Google Scholar
  4. 4.
    Antiplatelet Trialist Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 91–106Google Scholar
  5. 5.
    Antiplatelet Trials Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy. II. Maintainance of vascular graft or arterial potency by antiplatelet therapy. BMJ 308: 159–168CrossRefGoogle Scholar
  6. 6.
    Becker D, Windsor R, Ockene J et al. (1993) Setting the policy, education and research agenda to reduce tabacco use. AHA Prevention Conference III. Behavior change and compliance: Keys to improving cardiovascular health. Circulation 88: 1381–1386Google Scholar
  7. 7.
    Belchetz PE (1994) Hormonal replacement of postmenopausal women. N Engl J Med 33: 1062–1071Google Scholar
  8. 8.
    Bergkvist L, Adami HO, Person I et al. (1989) The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321: 293–297PubMedCrossRefGoogle Scholar
  9. 9.
    Bjerkelund CJ (1957) The effect of long-term treatment with dicoumarol in myocardial infarction. Acta Med Scand [Suppl] 330: 13–212Google Scholar
  10. 10.
    Breddin D, Loew D, Lechner K et al. (1980) Secondary prevention of myocardial infarction. A comparison of acetylsalicylic acid, placebo and phenprocommon. Haemostasis 9: 325–344Google Scholar
  11. 11.
    Burkhart F, Pfisterer M, Kiowski W et al. (1990) Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias. Basel Antiarrhythmic Study of Infarct Survival (BASIS) J Am Coll Cardiol 16: 1711–1718Google Scholar
  12. 12.
    Bush TL, Barrett-Connor E, Cowan LD et al. (1987) Cardiovascular mortality and noncon- traceptive use of estrogen in women: results of the Lipid Research Clinic Program Follow-up Study. Circulation 75: 1102–1109PubMedCrossRefGoogle Scholar
  13. 13.
    Cairns JA, Conolly S, Roberts R et al. (1997) Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 349: 675–682Google Scholar
  14. 14.
    Cavender JB, Rogers WJ, Fisher LD et al. (1992) Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10 year follow up. J Am Coll Cardiol 20: 287–294PubMedCrossRefGoogle Scholar
  15. 15.
    Ceremuzynski L, Kleczar E, Krzeminski-Pakula M et al. (1992) Effect of amiodarone on mortality after myocardial infarction. A double blind, placebo-controlled, pilot study. J Am Coll Cardiol 20: 1056–1062Google Scholar
  16. 16.
    Cleland JGF (1995) ACE-inhibitors for myocardial infarction: how should they be used? (Clinical perspective), Eur Heart J 16: 153–159PubMedGoogle Scholar
  17. 17.
    Colditz GA, Hankinson SE, Hutter DJ et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589–1593PubMedCrossRefGoogle Scholar
  18. 18.
    Cruickshank JM (1988) Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. BMJ 297: 1227–1230Google Scholar
  19. 19.
    Danish Study Group on Verapamil in Myocardial Infarction (1990) Effect of verapamil on mortality and major events after acute myocardial infarction (DAVIT-II). Am J Cardiol 66: 779–785CrossRefGoogle Scholar
  20. 20.
    Echt DS, Liebson PR, Mitchel B. and the CAST Investigators (1991) Mortality and morbidity in patients receiving encainide, flecainide or placebo. N Engl J Med 324: 781–788Google Scholar
  21. 21.
    EPSIM Research Group (1982) A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 307: 701–708CrossRefGoogle Scholar
  22. 22.
    Fagerstrom KO, Sawe U (1996) The pathophysiology of nicotine dependence: treatment options and the cardiovascular safety of nicotine. Cardiovasc Risk Factors 6: 135–143Google Scholar
  23. 23.
    Fagerstrom KO, Schneider NG (1989) Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire. J Behav Med 12: 159–182Google Scholar
  24. 24.
    Frasure-Smith N, Lesperance F, Talajic M (1993) Depression following myocardial infarction. Impact on 6-month survival. JAMA 270: 1819–1825PubMedCrossRefGoogle Scholar
  25. 25.
    Frasure-Smith N, Lesperance F, Talajic M (1995) Depression and 18-month prognosis after myocardial infarction. Circulation 91: 999–1005PubMedGoogle Scholar
  26. 26.
    Friedmann M, Thoresen CE, Gill JJ (1986) Alteration of type A behavior and its effect on cardiac recurrences in post myocardial infarction patients. Summary results of the recurrent coronary prevention project. Am Heart J 112: 653–665Google Scholar
  27. 27.
    Furberg CD, Psaty BM, Meyer JV (1995) Nifedipine: dose related increase in mortality in patients with coronary artery disease. Circulation 92: 1326–1331PubMedGoogle Scholar
  28. 28.
    Fuster V, Dyken ML, Vokonos PS, Heynekens C (1993) Aspirin as a therapeutic agent in cardiovascular disease. AHA Medical/Scientific Statement. Circulation 87: 659–675Google Scholar
  29. 29.
    Gerhard M, Ganz P (1995) How do we explain the clinical benefits of estrogen? From beside to bench. Circulation 92: 5–8PubMedGoogle Scholar
  30. 30.
    Gifford RH, Feinstein AR (1969) A critique of methodology in studies of anticoagulant therapy for acute myocardial infarction. N Engl J Med 280: 351–357PubMedCrossRefGoogle Scholar
  31. 31.
    Gilligan DM, Quyyumi A, Cannon RO (1994) Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89: 2445–2551Google Scholar
  32. 32.
    Glossmann AH, Helzer JE, Covey LS et al. (1990) Smoking, smoking cessation and major depression. JAMA 264: 1546–1549CrossRefGoogle Scholar
  33. 33.
    Goldstein F, Stampfer MJ, Manson JE et al. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335: 453–461CrossRefGoogle Scholar
  34. 34.
    Grady D, Cummings SR, Pettiti D et al. (1992) Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 117: 1038–1041Google Scholar
  35. 35.
    Gruppo Italiano per lo Studio della Soprawivenza nelP Infarto Miocardico GISSI–3 (1994) Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343: 1115–1122Google Scholar
  36. 36.
    Halhuber M (1987) Zeitgemafie Gesamtstrategie kardiologischer Rehabilitation. Therapie- woche 37: 2841–2842Google Scholar
  37. 37.
    Halhuber MJ (1986) Psychosoziale Aspekte der koronaren Herzkrankheit - Konsequenzen fiir Praxis, Lehre und Forschung nach dem Stand unseres Wissens 1985. In: Laskot F (Hrsg) Herzerkrankungen. Steinkopf, Darmstadt, S 357–363CrossRefGoogle Scholar
  38. 38.
    Hamalainen H, Luurila OJ, Kallio V, Knuts LR (1995) Reduction in sudden deaths and coronary mortality in myocardial infarction patients after rehabilitation 15-year follow up study. Eur Heart J 16: 1839–1844PubMedGoogle Scholar
  39. 39.
    Haskell WL, Alderman EL, Fair JM et al. (1994) Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: The Stanford Coronary Risk Intervention Project ( SCRIP ). Circulation 89: 975–990Google Scholar
  40. 40.
    Hedback B, Perk J, Wodlin P (1993) Long-term reduction of cardiac mortality after myocardial infarction: 10-year results of a comprehensive rehabilitation programme. Eur Heart J 14: 831–835PubMedCrossRefGoogle Scholar
  41. 41.
    Held PH, Yusuf S, Furberg CD (1989) Calcium blockers in acute myocardial infarction and unstable angina: an overview. BMJ 299: 1187–1192Google Scholar
  42. 42.
    Henningfield J (1995) Nicotine medications for smoking cessations. N Engl J Med 333: 1196–2003PubMedCrossRefGoogle Scholar
  43. 43.
    Hurt RD, Lauger GG, Offord KP et al. (1990) Nicotine replacement therapy with use of a transdermal nicotine patch - a randomized double-blind placebo controlled trial. Mayo Clin Proc 165: 1529–1539Google Scholar
  44. 44.
    International Anticoagulant Review Group (1970) Collaboration analysis of long term anticoagulant administration after acute myocardial infarction. Lancet 1: 203–209Google Scholar
  45. 45.
    ISIS–4 Collaborative Group (19995) ISIS–4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 345: 669–685Google Scholar
  46. 46.
    Kallio V, Hamalainen H, Hakkila J, Luurila OJ (1979) Reduction in sudden deaths by a multifactorial intervention programme after acute myocardial infarction. Lancet 2: 1091–1094PubMedCrossRefGoogle Scholar
  47. 47.
    Kannel WB, Sorlie P, Castelli WP et al. (1980) Blood pressure and survival after myocardial infarction - The Framingham Study. Am J Cardiol 45: 326–330PubMedCrossRefGoogle Scholar
  48. 48.
    Kober L, Torp-Pedersen C, Carlsen JE. for the Trandolapril Cardiac Evaluation (TRACE) Study Group (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333: 1670–1676Google Scholar
  49. 49.
    Kottke TE, Battista RN, DeFriese GH, Brekke ML (1988) Attributes of successfull smoking cessation interventions in medical practice. A metaanalysis of 39 controlled trials. JAMA 259: 2882–2889CrossRefGoogle Scholar
  50. 50.
    Kraseman EO, Traencker W (1989) Herz-Kreislaufkomplikationen und Verletzungen in Herzgruppen. Herz/Kreislauf 10: 421–425Google Scholar
  51. 51.
    Kunze M (1996) Epidemiology of nicotine dependence and general aspects of smoking cessation. Cardiovasc Risk Fact 6: 130–134Google Scholar
  52. 52.
    Langford HG, Stamler J, Wassertheil-Smoller S (1986) All cause mortality in the hypertension detection and follow up program. Findings with less severe hypertension, with and without other trials related to risk of mortality. Progr Cardiovasc Dis 29 [Suppl 1]: 29–54CrossRefGoogle Scholar
  53. 53.
    Madhavan S, Ooi WL, Cohen H, Alderman M (1994) Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 23: 395–401PubMedGoogle Scholar
  54. 54.
    Moss AJ, Hall WJ, Cannom DS et al. (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335: 1933–1940PubMedCrossRefGoogle Scholar
  55. 55.
    Meijer A, Verheng F, Werte C (1993) Aspirin versus Coumadin in the prevention of reocclu- sion and recurrent ischemia after successful thrombolysis. Results of the APRICOT study. Circulation 87: 1524–1530Google Scholar
  56. 56.
    O’Connor GT, Buring JE, Yusuf S (1989) An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 80: 234–244PubMedCrossRefGoogle Scholar
  57. 57.
    Oldridge NB, Guatt GH, Fauer ME, Rimm AA (1988) Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 260: 945–950Google Scholar
  58. 58.
    Ornish D, Brown SE, Scherwitz LW et al. (1990) Can lifestyle changes reverse coronary heart disease? The Life Style Heart Trial. Lancet 336: 129–133PubMedCrossRefGoogle Scholar
  59. 59.
    Pedersen TR, Kjekshus J, Berg K et al. (1994) Scandinavian Simvastasin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastasin Survival Study. Lancet 344: 1383–1389Google Scholar
  60. 60.
    Pekkanen J, Linn S, Heiss G et al. (1990) Ten year mortality from cardiovascular disease in relation to cholesterol level among men with and without cardiovascular disease. N Engl J Med 322: 1700–1707PubMedCrossRefGoogle Scholar
  61. 61.
    Pepine CJ (1996) Ongoing clinical trials of ACE-lnhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol 27: 1048–1052PubMedCrossRefGoogle Scholar
  62. 62.
    Peters RW, Brooks MM, Todd L, Liebson PR, Wilhelmsen L for the CAST investigators (1995) Smoking cessation and arrhythmic death: the CAST experience. J Am Coll Cardiol 26: 1287–1292Google Scholar
  63. 63.
    Pfeffer MA, Braunwald E (1990) Ventricular remodelling after myocardial infarction: experimental observations and clinical implications. Circulation 81: 1161–1172PubMedCrossRefGoogle Scholar
  64. 64.
    Pfeffer MA, Braunwald E, Moye LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial ( SAVE ). N Engl J Med 327: 669–677Google Scholar
  65. 65.
    Psaty BM, Heckbert SR, Koepsell TD et al. (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274: 620–625PubMedCrossRefGoogle Scholar
  66. 66.
    Rehnquist N, Hjemdohl P, Billing E. (1996) Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur HeartJ17: 76–81Google Scholar
  67. 67.
    Rengo F, Carbonin P, Pakor M et al. and CRIS Investigators (1996) A controlled trial of verapamil in patients after myocardial infarction. Results of the Calcium Antagonist Reinfarction Italian Study - CRIS. Am J Cardiol 77: 365–369Google Scholar
  68. 68.
    Roberts WC (1995) Prevention and arresting coronary atherosclerosis. Am Heart J 130: 580–600PubMedCrossRefGoogle Scholar
  69. 69.
    Ronnevik PK, Gundersen T, Abrahamsen AM (1985) Effects of smoking habits and timolol treatment on mortality and reinfarction in patients surviving acute myocardial infarction. Br Heart J 54: 134–139PubMedCrossRefGoogle Scholar
  70. 70.
    Ruberman W, Weinblatt E, Goldberg JD et al. (1984) Psychosocial influences on mortality after myocardial infarction. N Engl J Med 311: 552–559PubMedCrossRefGoogle Scholar
  71. 71.
    Sacks FM, Pfeffer MA, Moye LA et al. (1996) The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001–1009PubMedCrossRefGoogle Scholar
  72. 72.
    Schomig A, Neumann FJ, Kastrati A (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 334: 1084–1089PubMedCrossRefGoogle Scholar
  73. 73.
    Sellers EM, Navanjo CA, Kadlec K (1987) Do serotonin uptake inhibitors decrease smoking? J Clin Psychopharmacol 7: 417–420PubMedCrossRefGoogle Scholar
  74. 74.
    Siegrist J (1985) Koronargefahrdendes Verhalten. In: Basler HD, Florin J (Hrsg) Klinische Psychologie und korperliche Krankheiten. Kohlhammer, Stuttgart, S 79Google Scholar
  75. 75.
    Smith P, Arnesen H, Holme I (1990) The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 323: 147–152PubMedCrossRefGoogle Scholar
  76. 76.
    Smith SC jr, Blair SN, Criqui MH et al. (1995) Preventing heart attack and death in patients with coronary artery disease ( Consensus Panel Statement ). Circulation 92: 2–4Google Scholar
  77. 77.
    Stampfer MJ, Colditz GA, Willet WC et al. (1991) Postmenopausal estrogen therapy and cardiovascular disease - ten year follow up from the Nurses Health Study. N Engl J Med 325: 756–762PubMedCrossRefGoogle Scholar
  78. 78.
    Swan HJC, Gersh B, Graboys Th, Lillyot D (1996) Evaluation and Mangement of Risk factors for the individual patient. J Am Coll Cardiol 27: 1030–1039PubMedCrossRefGoogle Scholar
  79. 79.
    Tavazzi L et al. (1992) Long-term comprehensive care of cardiac patients. Recommendations by the Working Group on Rehabilitation of the European Society of Cardiology: Ischemic heart disease: risk stratification and intervention. Eur Heart J13 [Suppl C]: 3–19Google Scholar
  80. 80.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821 –828Google Scholar
  81. 81.
    The Cardiac Arrhythmias Suppression Trial II Investigators (1992) Effects of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327: 227–233CrossRefGoogle Scholar
  82. 82.
    The Lipid Research Clinics Coronary Primary Prevention Trial Results (1984) II. The relationship of reduction in incidence coronary heart disease to cholesterol lowering. JAMA 251: 365–374CrossRefGoogle Scholar
  83. 83.
    The Sixty - Plus Reinfarction Study Research Group (1980) A double blind trial to assess long term anticoagulant therapy in elderly patients after myocardial infarction. Lancet 2: 989–994Google Scholar
  84. 84.
    The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estro- gen/Progestin Interventions (PEPI) Trial. JAMA 273: 199–208CrossRefGoogle Scholar
  85. 85.
    Tonnesen P, Fryd V, Hansen M et al. (1988) Effect of nicotine chewing gum in combination with group counseling in the cessation of smoking. N Engl J Med 318: 15–18PubMedCrossRefGoogle Scholar
  86. 86.
    Unverdorben M, Vallbracht C, Ganser R et al. (1996) Kardiovaskulare Risiken der ambulan- ten Kardiologischen Rehabilitation. Herz/Kreislauf 28: 59–62Google Scholar
  87. 87.
    Van Camp SP, Peterson RA (1986) Cardiovascular complications of outpatient rehabilitation programs. JAMA 256: 1160–1163PubMedCrossRefGoogle Scholar
  88. 88.
    Viscoli CM, Horwitz RJ, Singer BH (1993) Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Ann Intern Med 118: 99–105PubMedGoogle Scholar
  89. 89.
    Wenger NK, Froelicher ES, Smith LK et al. (1995) Cardiac Rehabilitation as secondary prevention. Clinical practice guideline. Quick Reference Guide for Clinicians, No 17. AHCPR Pub No 96-0673, Oct 95, Rockville/MDGoogle Scholar
  90. 90.
    Wong ND, Nilson PWF, Kannel W (1991) Serum cholesterol as a prognostic factor after myocardial infarction. Ann Intern Med 115: 681–693Google Scholar
  91. 91.
    Working Group for the Study of Transdermal Nicotine in patients with coronary artery disease (1994) Nicotine-replacement therapy for patients with coronary artery disease. Arch Intern Med 154: 989–995Google Scholar
  92. 92.
    Yusuf S, Wittes J, Friedman L (1988) Overview of results of randomized clinical trials in heart disease I. Treatments following myocardial infarction. JAMA 260: 2088–2093Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • M. Pichler

There are no affiliations available

Personalised recommendations